Cost-effectiveness of active surveillance AS versus hemithyroidectomy for micropapillary thyroid cancer.
What about comparing thyroid radiofrequency ablation to AS?
- At present the patient with a micropapillary cancer of the thyroid is given only 2 options.
- Those who do not want surgery are left with long term AS.
- Even with just those two options 25% start and drop out of AS for surgery.
- If thyroid RFA was given as a third option there would be many more who would not want AS but also did not want invasive surgery.
- This study below shows how lobectomy was cost effective.
- There is no cost effective study now on thyroid RFA vs AS, but the costs of RFA are less than surgery and has not long term expense in most cases as the tumor is ablated as in the AS follow up regimen.
- Therefore the cost effectiveness of thyroid RFA will be even more than that for lobectomy as shown in this study.
- I predict that as we move into the age of thyroid RFA treatment, thyroid RFA for thyroid micro-cancer will be the treatment of choice for most patients as it has the advantage of removal of the cancer without surgery, and has the advantage over AS as the tumor is removed without long term fears of an enlarging cancer or lymph node spread and the extra expense of long term ultrasound follow up.
- At my center I offer thyroid RFA for micro-papillary thyroid cancer <1.5 cm.
- Call me at 310-393-8860 or email@example.com.
- Ask for Alicia
Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer
Presented at the annual meeting for the American Association of Endocrine Surgeons, April 10–12, 2016, in Baltimore, MD.